
|Articles|September 1, 2001
- Pharmaceutical Executive-09-01-2001
- Volume 0
- Issue 0
Profits and Promotion Under Attack
As policy makers struggle to devise a pharmacy benefit for Medicare patients, pressure mounts to impose spending limits on medications. In turn, consumer activists are challenging industry’s longtime claim that price controls will reduce investment in R&D for life-saving therapies.
Advertisement
Articles in this issue
about 24 years ago
New Playing Fieldsabout 24 years ago
Inefficiencies: Cutting Through the Jungleabout 24 years ago
Legislation: EC Proposes Changesabout 24 years ago
Flexing Their Budgets: Big Pharma Spend Trendsabout 24 years ago
Media Mix Town Meeting 2001: Much Ado About MediaNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: Organon CEO Kevin Ali Resigns
2
Organon CEO Kevin Ali to Resign Following Internal Investigation into Nexplanon Sales
3
GSK Enters $745 Million Worldwide Exclusive License Agreement with Empirico for Clinical-Stage First-In-Class Oligonucleotide Candidate
4
FDA Approves Single-Injection, Once-Monthly Maintenance Regimen for Lilly’s Omvoh in Ulcerative Colitis
5





